Valuation : BioNTech SE

Market Cap 24.02B 27.98B 22.49B 20.59B 38.79B 2,673B 38.9B 266B 104B 1,347B 105B 103B 4,458B P/E 2026 *
-17x
P/E 2027 * -18.5x
Enterprise Value 12.65B 14.74B 11.85B 10.85B 20.43B 1,408B 20.49B 140B 54.84B 710B 55.34B 54.15B 2,348B EV / Sales 2026 *
7x
EV / Sales 2027 * 7.72x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.03%
1 week+0.46%
Current month+22.99%
1 month+22.30%
3 months+19.78%
6 months+1.06%
Current year+17.02%
1 week 110.25
Extreme 110.25
116.87
1 month 88.2
Extreme 88.2
120.33
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.85
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%+0.46%+8.14%-5.28% 27.98B
+3.31%-3.70%+61.03%+103.64% 70.64B
+0.09%+0.69%+50.71%+93.40% 66.11B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
+0.72%+1.63%+35.57%-16.88% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
-0.59%+1.28%+306.56%+217.41% 12.51B
Average -0.20%+1.02%+84.17%+196.30% 30.04B
Weighted average by Cap. +0.44%+0.68%+67.11%+157.34%

Financials

2026 *2027 *
Net sales 1.81B 2.1B 1.69B 1.55B 2.92B 201B 2.93B 20.03B 7.83B 101B 7.9B 7.73B 335B 1.81B 2.11B 1.7B 1.55B 2.93B 202B 2.94B 20.1B 7.86B 102B 7.93B 7.76B 336B
Net income -1.38B -1.61B -1.29B -1.18B -2.23B -153B -2.23B -15.28B -5.97B -77.26B -6.03B -5.9B -256B -1.31B -1.52B -1.23B -1.12B -2.11B -146B -2.12B -14.51B -5.67B -73.38B -5.72B -5.6B -243B
Net Debt -11.37B -13.24B -10.64B -9.75B -18.36B -1,265B -18.41B -126B -49.27B -637B -49.72B -48.65B -2,110B -10.03B -11.69B -9.39B -8.6B -16.2B -1,116B -16.25B -111B -43.47B -562B -43.87B -42.93B -1,862B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
27/08/26 USD 111.40 -1.03% 1,552,570
26/08/26 USD 112.56 -1.31% 1,255,277
25/08/26 USD 114.05 +1.09% 1,359,359
24/08/26 USD 112.82 -3.22% 1,851,011
21/08/26 USD 116.57 +5.12% 2,960,787
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
95.63EUR
Average target price
103.92EUR
Spread / Average Target
+8.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock